Notification of Shares

RNS Number:6258Z
BioProgress PLC
04 July 2007


For Immediate Release                                                4 July 2007

                                BioProgress plc

                          Notification of Shareholding


London, UK, 4 July 2007: BioProgress plc ('BioProgress' or the 'Company') (AIM:
BPRG), the specialty pharma and healthcare company, was notified on 2 July that
Barclays Stockbrokers Limited has a notifiable interest in the company of
10,577,770 shares representing 5.79% of the issued share capital of BioProgress
plc.

                                    - ENDS -


For further information:


BioProgress Plc                                     + 44 (0) 20 7098 9881

Richard Trevillion, CEO

Steve Martin, CDO

Hiral Patel, CFO

Buchanan Communications                             + 44 (0) 20 7466 5000

Rebecca Skye Dietrich

Mark Court


About BioProgress

BioProgress plc is an innovative specialty pharmaceutical and healthcare
business based around its platform technologies in polymer and film systems.
Listed on London's AIM in May 2003 and on US NASDAQ in October 2004, the company
has over 80 patents granted or in application within 24 patent families and has
product development agreements and strategic alliances with several global
companies. As a virtually integrated business, BioProgress has acquired sales
and marketing resources within Europe and the US as a launch mechanism for its
own pharmaceutical products. The business continues to develop innovative
delivery mechanisms using its XGELTM polymer technology, replacing the need to
use animal-derived gelatine in pharmaceutical and healthcare products. For
further information please go to www.bioprogress.com


Forward-Looking Information.

The Ordinary Shares of BioProgress plc are registered under the US Securities
and Exchange Act of 1934.  To the extent that this announcement contains certain
"forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995, this paragraph applies.  These statements are
based on management's current expectations and are subject to uncertainty and
changes in circumstances.  Actual results may vary materially from the
expectations contained in the forward-looking statements.  The forward-looking
statements in this release include statements addressing future financial and
operating results and the timing and benefits of the reorganisation.  Detailed
information about factors pertinent to the business of the company that could
cause actual results to differ is set forth in the Company"s filings with the
Securities and Exchange Commission.  The Company is under no obligation to (and
expressly disclaim any such obligation to) update or alter its forward-looking
statements whether as a result of new information, future events or otherwise.
This announcement is for information only and does not constitute an offer or
invitation to acquire or dispose of any securities or investment advice.  The
distribution of the announcement and/or issue of securities in certain
jurisdictions may be restricted by law.  Persons into whose possession this
announcement comes are required to inform themselves about and to observe such
restrictions.



                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

HOLMGGGNRDNGNZG

Bioprogress (LSE:BPRG)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024